Dr. Gordon's research focuses on early-phase clinical trials and novel therapeutic strategies for solid tumors. She has contributed to studies investigating combination therapies, such as regorafenib with sildenafil in advanced solid tumors, and the use of veliparib and bevacizumab in ovarian and peritoneal cancers. Her work also includes post hoc analyses on BRCA status and treatment toxicities in gynecologic cancers . Clinically, Dr. Gordon is dedicated to advancing treatments for lung cancer. She leads the Thoracic Malignancy Oncologic Group at the Sidney Kimmel Comprehensive Cancer Center, a multidisciplinary initiative aimed at improving care for lung and aerodigestive cancers
Sarah W. Gordon, DO
Medical Director, Bodine Infusion
Clinical Co-Director of Phase 1 Program/Early Drug Development Office, Sidney Kimmel Comprehensive Cancer Center
Lung Program Leader, Enterprise Jefferson Health
Associate Professor
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia , PA 19107
Medical Director, Bodine Infusion
Clinical Co-Director of Phase 1 Program/Early Drug Development Office, Sidney Kimmel Comprehensive Cancer Center
Lung Program Leader, Enterprise Jefferson Health
Associate Professor
RESEARCH & CLINICAL INTEREST
EDUCATION
Medical School
Philadelphia College of Osteopathic Medicine
Residency
Drexel University College of Medicine, Hahnemann University Hospital
Fellowship
Hematology/Oncology Fellowship, Virginia Commonwealth University
Publications
- A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors
- Case report: paradoxically reversible perfusion defects on vasodilator stress imaging in a case of metastatic coronary compression
- Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
- A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
- Remote Ischemic Pre-Conditioning Attenuates Adverse Cardiac Remodeling and Mortality Following Doxorubicin Administration in Mice
Certifications
- Internal Medicine
- Internal Medicine, Hematology
- Internal Medicine, Oncology